Abstract
Introducción: Early published series suggest that most renal transplant recipients remain at high risk of SARS-CoV-2 infection due to poor humoral response after vaccination. The aim was to study the occurrence of adverse events after two doses of mRNA-1273 vaccine in a population of renal transplant recipients.Material and Method: Analytical, observational, and prospective study. Subjects were injected with two doses of mRNA-1273 vaccine against SARS-CoV-2 according to the schedule established by the laboratory. After injection of each dose, and up to 72 hours later, participants recorded local and/or systemic symptoms and their intensity.Results: 187 patients were included. Eighteen percent of them became infected with SARS-CoV-2 in the pre-vaccination period or between the 1st and 2nd dose. The incidence of adverse events was 91.2%. Of these, the incidence of local (62%) was higher than that of systemic (55%). Past infection was a risk factor for the occurrence of local adverse events after vaccination (OR= 2.4; p=0.045). The same association was detected for systemic adverse events, which were more frequent among those who had passed the disease (OR=3.83; p=0.003).Conclusions: The mRNA-1273 vaccine does not appear to cause serious side effects. The incidence of local and systemic adverse events was higher in those patients with past disease.
Publisher
Sociedad Espanola de Enfermeria Nefrologica
Reference22 articles.
1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated 315 with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-3.
2. Martín De Francisco A. Vacunas Sars-Cov 2. Nefrología. 2021 [cited 16 May 2022]. Available at: https://nefrologiaaldia.org./es-articulo-vacunas-saars-cov2-marzo-2021-366
3. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patient with renal disease. Am J Kidney Dis. 2005;46(6):997-1011.
4. Haddadin Z, Krueger K, Thomas LD, Overton ET, Ison M, Halasa N. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipient. Am J transplant. 2021;21:938-49.
5. Cunningham AL, Garçon N, Leo O, Friedland LR, Strugnell R, Laupèze B, et al. Vaccine development: from concept to early testing. Vaccine.2016;34(52):6655-64.